LYEL

Lyell is a pre-revenue, late-stage clinical cell-therapy company, and the financials leave no ambiguity: FY2025 'revenue' of $36.0K is immaterial (down 41% YoY and essentially rounding noise), so the headline P/S of ~9,096x is meaningless. What matters is the loss engine and the fuel tank. The company posted a -$274M net loss and burned -$150M in operating cash, while holding just $60.2M in cash & equivalents (down 43% YoY). That is well under half a year of runway at the FY2025 burn rate — and management explicitly warns it will 'require substantial additional capital' and expects losses to 'increase' as it runs two pivotal trials (PiNACLE and the Phase 3 PiNACLE-H2H head-to-head) plus the newly in-licensed solid-tumor program LYL273. A financing is not a risk; it is a near-mathematical certainty, and at a $327M market cap it will be materially dilutive to the remaining 23.3M shares.

The capital structure already shows the scars. Shares outstanding fell 92.1% YoY (consistent with a large reverse split), diluted EPS is -$16.06, and accumulated deficit sits at -$1.62B against $248M of stockholders' equity that shrank 35% in a year. The balance sheet is not levered (liabilities/equity 0.37x, current assets $261M vs $49.4M current liabilities), so the immediate danger is not creditors — it is the cash line depleting toward a raise. ROE of -110.6% reflects equity being consumed by R&D with no offsetting product income, and the revenue history (a one-off $84.7M in FY2022 collapsing to five figures since) confirms there is no recurring commercial business to underwrite the stock.